175 related articles for article (PubMed ID: 31570853)
1. Targeting PML in triple negative breast cancer elicits growth suppression and senescence.
Arreal L; Piva M; Fernández S; Revandkar A; Schaub-Clerigué A; Villanueva J; Zabala-Letona A; Pujana M; Astobiza I; Cortazar AR; Hermanova I; Bozal-Basterra L; Arruabarrena-Aristorena A; Crespo JR; Valcarcel-Jimenez L; Zúñiga-García P; Canals F; Torrano V; Barrio R; Sutherland JD; Alimonti A; Martin-Martin N; Carracedo A
Cell Death Differ; 2020 Apr; 27(4):1186-1199. PubMed ID: 31570853
[TBL] [Abstract][Full Text] [Related]
2. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
[TBL] [Abstract][Full Text] [Related]
3. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.
Brasó-Maristany F; Filosto S; Catchpole S; Marlow R; Quist J; Francesch-Domenech E; Plumb DA; Zakka L; Gazinska P; Liccardi G; Meier P; Gris-Oliver A; Cheang MC; Perdrix-Rosell A; Shafat M; Noël E; Patel N; McEachern K; Scaltriti M; Castel P; Noor F; Buus R; Mathew S; Watkins J; Serra V; Marra P; Grigoriadis A; Tutt AN
Nat Med; 2016 Nov; 22(11):1303-1313. PubMed ID: 27775704
[TBL] [Abstract][Full Text] [Related]
4. PML promotes metastasis of triple-negative breast cancer through transcriptional regulation of HIF1A target genes.
Ponente M; Campanini L; Cuttano R; Piunti A; Delledonne GA; Coltella N; Valsecchi R; Villa A; Cavallaro U; Pattini L; Doglioni C; Bernardi R
JCI Insight; 2017 Feb; 2(4):e87380. PubMed ID: 28239645
[TBL] [Abstract][Full Text] [Related]
5. SPAG5 upregulation contributes to enhanced c-MYC transcriptional activity via interaction with c-MYC binding protein in triple-negative breast cancer.
Li M; Li A; Zhou S; Lv H; Yang W
J Hematol Oncol; 2019 Feb; 12(1):14. PubMed ID: 30736840
[TBL] [Abstract][Full Text] [Related]
6. PIM1: a promising target in patients with triple-negative breast cancer.
Zhao W; Qiu R; Li P; Yang J
Med Oncol; 2017 Aug; 34(8):142. PubMed ID: 28721678
[TBL] [Abstract][Full Text] [Related]
7. E6AP ubiquitin ligase regulates PML-induced senescence in Myc-driven lymphomagenesis.
Wolyniec K; Shortt J; de Stanchina E; Levav-Cohen Y; Alsheich-Bartok O; Louria-Hayon I; Corneille V; Kumar B; Woods SJ; Opat S; Johnstone RW; Scott CL; Segal D; Pandolfi PP; Fox S; Strasser A; Jiang YH; Lowe SW; Haupt S; Haupt Y
Blood; 2012 Jul; 120(4):822-32. PubMed ID: 22689861
[TBL] [Abstract][Full Text] [Related]
8. Korean red ginseng extract induces proliferation to differentiation transition of human acute promyelocytic leukemia cells via MYC-SKP2-CDKN1B axis.
Jo S; Lee H; Kim S; Lee CH; Chung H
J Ethnopharmacol; 2013 Nov; 150(2):700-7. PubMed ID: 24095829
[TBL] [Abstract][Full Text] [Related]
9. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
[TBL] [Abstract][Full Text] [Related]
10. Higher levels of TIMP-1 expression are associated with a poor prognosis in triple-negative breast cancer.
Cheng G; Fan X; Hao M; Wang J; Zhou X; Sun X
Mol Cancer; 2016 Apr; 15(1):30. PubMed ID: 27130446
[TBL] [Abstract][Full Text] [Related]
11. Expression of p27 and c-Myc by immunohistochemistry in breast ductal cancers in African American women.
Khan F; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
Ann Diagn Pathol; 2018 Jun; 34():170-174. PubMed ID: 29715580
[TBL] [Abstract][Full Text] [Related]
12. Promyelocytic Leukemia (PML) gene regulation: implication towards curbing oncogenesis.
Datta N; Islam S; Chatterjee U; Chatterjee S; Panda CK; Ghosh MK
Cell Death Dis; 2019 Sep; 10(9):656. PubMed ID: 31506431
[TBL] [Abstract][Full Text] [Related]
13. Cip2a promotes cell cycle progression in triple-negative breast cancer cells by regulating the expression and nuclear export of p27Kip1.
Liu H; Qiu H; Song Y; Liu Y; Wang H; Lu M; Deng M; Gu Y; Yin J; Luo K; Zhang Z; Jia X; Zheng G; He Z
Oncogene; 2017 Apr; 36(14):1952-1964. PubMed ID: 27694903
[TBL] [Abstract][Full Text] [Related]
14. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
[TBL] [Abstract][Full Text] [Related]
15. β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
Xu J; Chen Y; Huo D; Khramtsov A; Khramtsova G; Zhang C; Goss KH; Olopade OI
Mol Carcinog; 2016 May; 55(5):431-9. PubMed ID: 25663530
[TBL] [Abstract][Full Text] [Related]
16. PML modulates epigenetic composition of chromatin to regulate expression of pro-metastatic genes in triple-negative breast cancer.
Fracassi C; Ugge' M; Abdelhalim M; Zapparoli E; Simoni M; Magliulo D; Mazza D; Lazarevic D; Morelli MJ; Collas P; Bernardi R
Nucleic Acids Res; 2023 Nov; 51(20):11024-11039. PubMed ID: 37823593
[TBL] [Abstract][Full Text] [Related]
17. Stratification and therapeutic potential of PML in metastatic breast cancer.
Martín-Martín N; Piva M; Urosevic J; Aldaz P; Sutherland JD; Fernández-Ruiz S; Arreal L; Torrano V; Cortazar AR; Planet E; Guiu M; Radosevic-Robin N; Garcia S; Macías I; Salvador F; Domenici G; Rueda OM; Zabala-Letona A; Arruabarrena-Aristorena A; Zúñiga-García P; Caro-Maldonado A; Valcárcel-Jiménez L; Sánchez-Mosquera P; Varela-Rey M; Martínez-Chantar ML; Anguita J; Ibrahim YH; Scaltriti M; Lawrie CH; Aransay AM; Iovanna JL; Baselga J; Caldas C; Barrio R; Serra V; Vivanco Md; Matheu A; Gomis RR; Carracedo A
Nat Commun; 2016 Aug; 7():12595. PubMed ID: 27553708
[TBL] [Abstract][Full Text] [Related]
18. Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.
Song W; Hwang Y; Youngblood VM; Cook RS; Balko JM; Chen J; Brantley-Sieders DM
Oncogene; 2017 Oct; 36(40):5620-5630. PubMed ID: 28581527
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
[TBL] [Abstract][Full Text] [Related]
20. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
